Netupitant
Olanzapine-contained Four-drug Antiemetic
Jiuda ZhaoSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Olanzapine-contained Four-drug Antiemetic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olanzapine Jiuda Zhao | Phase 3 | B |
Tropisetron Jiuda Zhao | Phase 3 | B |
Same molecule, other indications
Netupitant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →